CLAIMS

1. A pharmaceutical formulation comprising a therapeutically effective amount of dronedarone or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of ranolazine, and a pharmaceutically acceptable carrier.

2. The formulation of claim 1, formulated for intravenous administration or oral administration.

3. The formulation of claim 1, wherein the formulation is in tablet form or capsule form.

4. The formulation of claim 3, wherein the tablet or capsule comprises from 25 mg to 600 mg of the dronedarone or the salt thereof.

5. The formulation of claim 3, wherein the tablet or capsule comprises from 50 mg to 200 mg of the dronedarone or the salt thereof.

6. The formulation of any one of claims 3-5, wherein the tablet or capsule comprises from 50 mg to 1000 mg of the ranolazine.

7. The formulation of claim 6, wherein the tablet or capsule comprises from 100 mg to 750 mg of the ranolazine.

8. The formulation of claim 3, wherein the tablet or capsule comprises from 100 mg to 750 mg of the ranolazine and from 50 mg to 200 mg of the dronedarone or the salt thereof.

9. The formulation of any one of claims 1-8, wherein the salt of dronedarone is dronedarone hydrochloride.

10. The formulation of any one of claims 1-8, wherein the salt of dronedarone is a phosphoric acid addition salt.

11. The formulation of any one of claims 1-10, wherein the ranolazine is formulated for sustained release.

12. The formulation of any one of claims 1-11, wherein the dronedarone or the pharmaceutically acceptable salt thereof is formulated for immediate release or sustained release.

13. A tablet comprising a therapeutically effective amount of dronedarone or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of ranolazine, and a pharmaceutically acceptable carrier.

14. The tablet of claim 13, wherein the tablet comprises from 25 mg to 600 mg of the dronedarone or the salt thereof.

15. The tablet of claim 13 or 14, wherein the tablet comprises from 50 mg to 1000 mg of the ranolazine.

16. The tablet of claim 13, wherein the tablet comprises from 50 mg to 200 mg of the dronedarone or the salt thereof.

17. The tablet of claim 16, comprising from 100 mg to 750 mg of the ranolazine.

18. The tablet of any one of claims 13-17, wherein the salt of dronedarone is dronedarone hydrochloride.

19. The table of any one of claims 13-17, wherein the salt of dronedarone is a phosphoric acid addition salt.